WHO Suspendes Hydroxychloroquine Trials Pending Safety Data

The Solidarity trial aims to assess the safety and efficacy of treatments for COVID-19, involving over 400 hospitals across 75 countries. A recent study published in The Lancet highlighted concerns about Hydroxychloroquine, prompting a temporary pause in its trial arm for safety review. The trial's executive group is conducting a comprehensive analysis of global data to evaluate the drug's risks and benefits. While Hydroxychloroquine is generally safe for autoimmune diseases and malaria, its use in COVID-19 is under scrutiny. WHO will provide updates as more information becomes available.

What was the purpose of initiating the Solidarity trial?

What were the findings of the observational study published in The Lancet regarding Hydroxychloroquine and Chloroquine?

What will the review by the executive group consider in terms of data?

What actions did the executive group of the Solidarity trial take regarding the Hydroxychloroquine arm?

What is the general safety status of Hydroxychloroquine and Chloroquine for patients with autoimmune diseases or malaria?